Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 3/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 3/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | WNT1 | P04628 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775974 | 0.83 | ATAD2 (0.40) | DYRK1AWNT1LRRK2NR4A2CYP1A2 | |
| SCHEMBL5770570 | 0.82 | NR4A2 (0.38) | NR4A2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL5872932 | 0.80 | ATAD2 (0.40) | PIM1LRRK2NR4A2CYP1A2KDM4E | |
| SCHEMBL5873172 | 0.78 | DYRK1A (0.43) | MAP2K4PIM1DYRK1AWNT1 | |
| SCHEMBL5771961 | 0.78 | KDM4E (0.55) | MAP2K4TTKKDM4EALDH1A1IDO1 | |
| SCHEMBL5769485 | 0.76 | NR4A2 (0.38) | PIM1NR4A2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL5873217 | 0.76 | PIM1 (0.38) | PIM1LRRK2CYP1A2KDM4EALDH1A1 | |
| SCHEMBL5767627 | 0.74 | MAP2K4 (0.43) | MAP2K4PIM1DYRK1AWNT1LRRK2 | |
| SCHEMBL5770580 | 0.74 | CDC7 (0.47) | CYP1A2KDM4EALDH1A1 | |
| SCHEMBL5873062 | 0.72 | CDC7 (0.47) | PIM1CYP1A2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | MAP2K4 2844/4885TTK 624/4885AXL 4599/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | MAP2K4 2844/4885TTK 624/4885AXL 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.